Trial Profile

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Mar 2026 According to an EyePoint Pharmaceuticals media release, the company presented DAVIO 2 trial in wet AMD data and VERONA trial in DME data at the 49th Annual Macula Society Meeting.
02 Oct 2025 Actual primary completion date changed from 7 Nov 2023 to 29 Nov 2023.
09 Jul 2025 According to an EyePoint Pharmaceuticals media release, results from this study presented at the 2025 Association for Research in Vision and Ophthalmology (ARVO) conference in Salt Lake City, Utah.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com